Recombinant human LH supplementation versus supplementation with urinary hCG-based LH activity during controlled ovarian stimulation in the long GnRH-agonist protocol: a matched case–control study

References

• Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, Coppola M, et al. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism. Reprod Biomed Online 2009;18:9–14.
   PubMed Web of Science ®Google Scholar
• Fleming R, Lloyd F, Herbert M, Fenwick J, Griffiths T, Murdoch A. Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle-stimulating hormone. Hum Reprod 1998;13:1788–1792.
   PubMed Web of Science ®Google Scholar
• Westergaard LG, Laursen SB, Andersen CY. Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. Hum Reprod 2000;15:1003–1008.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum L, Bungum M, Andersen CY. Ovarian response and pregnancy outcome related to mid-follicular LH levels in women undergoing assisted reproduction with GnRH agonist down-regulation and recombinant FSH stimulation. Hum Reprod 2002;17:2016–2021.
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Zikopoulos K, Schiettecatte J, Smitz J, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Profound LH suppression after GnRH antagonist administration is associated with a significantly higher ongoing pregnancy rate in IVF. Hum Reprod 2004;19:2490–2496.
   PubMed Web of Science ®Google Scholar
• Merviel P, Antoine JM, Mathieu E, Millot F, Mandelbaum J, Uzan S. Luteinizing hormone concentrations after gonadotropin-releasing hormone antagonist administration do not influence pregnancy rates in in vitro fertilization-embryo transfer. Fertil Steril 2004;82:119–125.
   PubMed Web of Science ®Google Scholar
• Cabrera RA, Stadtmauer L, Mayer JF, Gibbons WE, Oehninger S. Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone. Fertil Steril 2005;83:42–48.
   PubMed Web of Science ®Google Scholar
• Loumaye E, Engrand P, Howles CM, O’Dea L. Assessment of the role of serum luteinizing hormone and estradiol response to follicle-stimulating hormone on in vitro fertilization treatment outcome. Fertil Steril 1997;67:889–899.
   PubMed Web of Science ®Google Scholar
• Chappel SC, Howles C. Re-evaluation of the roles of luteinizing hormone and follicle-stimulating hormone in the ovulatory process. Hum Reprod 1991;6:1206–1212.
   PubMed Web of Science ®Google Scholar
• Kolibianakis EM, Collins J, Tarlatzis B, Papanikolaou E, Devroey P. Are endogenous LH levels during ovarian stimulation for IVF using GnRH analogues associated with the probability of ongoing pregnancy? A systematic review. Hum Reprod Update 2006;12:3–12.
   PubMed Web of Science ®Google Scholar
• Ferraretti AP, Gianaroli L, Magli MC, D’angelo A, Farfalli V, Montanaro N. Exogenous luteinizing hormone in controlled ovarian hyperstimulation for assisted reproduction techniques. Fertil Steril 2004;82:1521–1526.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Bungum M, Bungum L, Yding Andersen C. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: An opening study. Reprod Biomed Online 2004;8:635–643.
   PubMed Web of Science ®Google Scholar
• Lamminen T, Huhtaniemi I. A common genetic variant of luteinizing hormone; relation to normal and aberrant pituitary-gonadal function. Eur J Pharmacol 2001;414:1–7.
   PubMed Web of Science ®Google Scholar
• Takahashi K, Karino K, Kanasaki H, Miyazaki K. Altered kinetics of pituitary response to gonadotropin-releasing hormone in women with variant luteinizing hormone: Correlation with ovulatory disorders. Horm Res 2004;61:27–32.
   Google Scholar
• Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe G, Picconeri MG. Use of recombinant follicle-stimulating hormone (Gonal F) and recombinant luteinizing hormone (Luveris) for multiple follicular stimulation in patients with a suboptimal response to in vitro fertilization. Fertil Steril 2003;79:1037–1038.
   PubMed Web of Science ®Google Scholar
• De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, De Palo R, et al. Italian Collaborative Group on Recombinant Human Luteinizing Hormone. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod 2005;20:390–396.
   PubMed Web of Science ®Google Scholar
• De Placido G, Mollo A, Clarizia R, Strina I, Conforti S, Alviggi C. Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. Fertil Steril 2006;85:247–250.
   PubMed Web of Science ®Google Scholar
• Ludwig M, Bühler K, Diedrich K, Felberbaum RE, Rabe T. Wirksamkeit von rekombinantem humanem FSH im Vergleich zu urinärem hMG nach Downregulation im langen Protokoll – Eine Analyse von 24.764 ART-Zyklen in Deutschland. J Reproduktionsmed Endokrinol 2004;1:284–288.
   Google Scholar
• Directive 2004/23/EC of the European Parliament and of the Council of 31 March 2004 on setting standards of quality and safety for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. Available from http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2004:102:0048:0058.en.pdf.
   Google Scholar
• Commission Directive 2006/17/EC of 8 February 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. Available from http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:038:0040:0052.en.pdf.
   Google Scholar
• Commission Directive 2006/86/EC of 24 October 2006 implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells. Available from http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2006:294:0032:0050.en.pdf.
   Google Scholar
• D·I·R Jahrbuch 2007 [Annual D·I·R report 2007]. Available from http://www.deutsches-ivf-register.de/pdf-downloads/dirjahrbuch2007.pdf [in German].
   Google Scholar
• Bühler K, Bals-Pratsch M, Kupka MS. The Board of Trustees. D·I·R Annual 2009. J Reproduktionsmed Endokrinol 2010;7:470–497.
   Google Scholar
• Devroey P, Boostanfar R, Koper NP, Mannaerts BM, Ijzerman-Boon PC, Fauser BC; ENGAGE Investigators A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first seven days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24:3063–3072.
   PubMed Web of Science ®Google Scholar
• Trinchard-Lugan I, Khan A, Porchet HC, Munafo A. Pharmacokinetics and pharmacodynamics of recombinant human chorionic gonadotrophin in healthy male and female volunteers. Reprod Biomed Online 2002;4:106–115.
   Google Scholar
• Menon KM, Munshi UM, Clouser CL, Nair AK. Regulation of luteinizing hormone/human chorionic gonadotropin receptor expression: A perspective. Biol Reprod 2004;70:861–866.
   PubMedGoogle Scholar
• Grøndahl ML, Borup R, Lee YB, Myrhøj V, Meinertz H, Sørensen S. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. Fertil Steril 2009;91:1820–1830.
   PubMed Web of Science ®Google Scholar
• Marrs R, Meldrum D, Muasher S, Schoolcraft W, Werlin L, Kelly E. Randomized trial to compare the effect of recombinant human FSH (follitropin alfa) with or without recombinant human LH in women undergoing assisted reproduction treatment. Reprod Biomed Online 2004;8:175–182.
   PubMed Web of Science ®Google Scholar
• Bosch E, Labarta C, Simon C, Remohi J, Pellicer A. The impact of luteinizing hormone supplementation in gonadotropin releasing hormone antagonist cycles. An age adjusted randomized trail. Fertil Steril 2008:90:41.
   Google Scholar
• Lisi F, Rinaldi L, Fishel S, Caserta D, Lisi R, Campbell A. Evaluation of two doses of recombinant luteinizing hormone supplementation in an unselected group of women undergoing follicular stimulation for in vitro fertilization. Fertil Steril 2005;83:309–315.
   PubMed Web of Science ®Google Scholar
• Franco JG Jr, Baruffi RL, Oliveira JB, Mauri AL, Petersen CG, Contart P, Felipe V. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: A matched case-control study. Reprod Biol Endocrinol 2009;7:58.
   PubMed Web of Science ®Google Scholar